Literature DB >> 2965854

Identification of high-risk patients with silent myocardial ischemia after percutaneous transluminal coronary angioplasty by multilead monitoring.

M Krucoff1.   

Abstract

Quantification of total ischemic burden can be improved by use of microprocessor-driven, multichannel, digital, ST-monitoring devices. ST deviation recorded during angioplasty provides a patient-specific template for identification of patients at increased risk for coronary events after angiographically successful dilation. In patients with ST-segment elevation, evidence of these ST "fingerprint" patterns are associated with elevated risk for coronary events in the postangioplasty period. Such risk is not seen in patients with ST-segment depression or with no ST changes. The increased monitoring capability afforded with digitized 3- or 12-lead monitoring creates new criteria for what constitutes accurate determination of total ischemic burden.

Entities:  

Mesh:

Year:  1988        PMID: 2965854     DOI: 10.1016/0002-9149(88)90053-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Residual area at risk after anterior myocardial infarction: are ST segment changes during coronary angioplasty a reliable indicator? A comparison with technetium 99m-labeled sestamibi single-photon emission computed tomography.

Authors:  M Faraggi; P G Steg; D Francois; L Sarda; J M Foult; D Daou; P Assayag; D Le Guludec
Journal:  J Nucl Cardiol       Date:  1997 Jan-Feb       Impact factor: 5.952

2.  Observer variability and optimal criteria of transient ischemia during ST monitoring with continuous 12-lead ECG.

Authors:  Tomas Jernberg; Jörgen Cronblad; Bertil Lindahl; Lars Wallentin
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-07       Impact factor: 1.468

3.  Failure to predict intraoperative myocardial ischaemia in patients with coronary artery disease.

Authors:  H Smith; H Nathan; M Harrison
Journal:  Can J Anaesth       Date:  1989-09       Impact factor: 5.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.